Pharma Journalist -

Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced that the U.S.…
Read More...

Strata Oncology announced an agreement with Epizyme to support patient identification and enrollment for Epizyme’s ongoing Phase 2 clinical trial of tazemetostat in patients with…
Read More...

Veeva Systems (VEEV) announced a new cloud application dubbed Veeva Vault Submissions Publishing that incorporates publishing capabilities within Veeva Vault RIM to accelerate…
Read More...

Portola Pharmaceuticals, Inc.® (PTLA) announced that it has signed a $150 million royalty agreement with HealthCare Royalty Partners (HCR). Under the terms of the agreement, Portola…
Read More...

Teva Pharmaceutical Industries Ltd., announced that it has filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market…
Read More...

Lysogene announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to LYS-GM101, the company’s gene therapy drug candidate for treatment of GM1…
Read More...

Cocoon Biotech, Inc., is a biotechnology company focused on utilizing its silk protein-based drug delivery technology for the development of formulations to treat osteoarthritis and…
Read More...

GE Healthcare’s FlexFactory manufacturing platform has been selected to expand production capacity at Arven Pharmaceuticals' facility in Kirklareli, Turkey. With this expanded…
Read More...

HOPE BIOSCIENCES, INC. announced that it has acquired exclusive and worldwide rights to develop and commercialize HOPE 777, a unique MERTK/AXL/pan-c-MET tyrosine kinase inhibitor…
Read More...

Meridian Laboratories, Inc., a Buffalo, IL based specialty-oncology drug development company, announced today that it has entered into a definitive agreement with Apobiologix, a part of…
Read More...